- Home
- XENE vs APLS Comparison
XENE vs APLS Comparison
Compare XENE & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XENE
- APLS
- Stock Information
- Founded
- XENE 1996
- APLS 2009
- Country
- XENE Canada
- APLS United States
- Employees
- XENE N/A
- APLS N/A
- Industry
- XENE Biotechnology: Pharmaceutical Preparations
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- XENE Health Care
- APLS Health Care
- Exchange
- XENE Nasdaq
- APLS Nasdaq
- Market Cap
- XENE 2.3B
- APLS 2.2B
- IPO Year
- XENE 2014
- APLS 2017
- Fundamental
- Price
- XENE $32.05
- APLS $17.69
- Analyst Decision
- XENE Strong Buy
- APLS Buy
- Analyst Count
- XENE 11
- APLS 19
- Target Price
- XENE $54.82
- APLS $37.67
- AVG Volume (30 Days)
- XENE 977.8K
- APLS 2.1M
- Earning Date
- XENE 08-07-2025
- APLS 07-31-2025
- Dividend Yield
- XENE N/A
- APLS N/A
- EPS Growth
- XENE N/A
- APLS N/A
- EPS
- XENE N/A
- APLS N/A
- Revenue
- XENE $7,500,000.00
- APLS $775,839,000.00
- Revenue This Year
- XENE N/A
- APLS $1.01
- Revenue Next Year
- XENE $253.71
- APLS $22.14
- P/E Ratio
- XENE N/A
- APLS N/A
- Revenue Growth
- XENE N/A
- APLS 48.04
- 52 Week Low
- XENE $26.74
- APLS $16.10
- 52 Week High
- XENE $46.00
- APLS $42.47
- Technical
- Relative Strength Index (RSI)
- XENE 51.34
- APLS 42.98
- Support Level
- XENE $31.22
- APLS $18.26
- Resistance Level
- XENE $33.46
- APLS $19.96
- Average True Range (ATR)
- XENE 1.28
- APLS 0.84
- MACD
- XENE 0.27
- APLS -0.08
- Stochastic Oscillator
- XENE 68.60
- APLS 19.22
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.